Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Knee implants helped revenues and profits to kick in at Smith & Nephew last year

In the 12 months ended December 31 revenues grew 2% to US$4.77bn, while operating profits jumped 16% to US$934mln
artificial hip and knee
The FTSE 100 group makes artificial hips and knees as well as wound dressings and other medical products

Medical products group Smith & Nephew PLC (LON:SN.) saw revenues and operating profits rise in 2017.

In the 12 months ended December 31 revenues grew 2% to US$4.77bn (2016: US$4.67bn), while operating profits, which exclude the sale of the gynaecology business in 2016, jumped 16% to US$934mln (2016: US$801mln).

Emerging markets now account for 16% of sales

The FTSE 100 firm – which makes artificial hips and knees as well as wound dressings – said the solid performance was driven by “market-beating growth” in its knee implants business and double-digit growth in emerging markets.

Those gains were somewhat offset by a fall in sales in S&N’s arthroscopy and European advanced wound care businesses.

READ: JP Morgan upgrades Smith & Nephew

A one-off benefit from the recent US tax reforms meant the company’s tax rate for 2017 was just 17.1% (2016: 23.8%), although it expects rates to be between 20-21% going forward – that’s still better than analysts had initially estimated.

Adjusted earnings per share came in at 94.5 cents (2016: 82.6 cents0 reflecting the improved trading and lower tax rate.

Given the strong showing, Smith & Nephew increased its full-year dividend by 14% to 35 cents a share.

‘Delivering on promises’

“We delivered on our promises to improve the top and bottom line in 2017,” said chief executive Olivier Bohuon.

“Our Knee Implants franchise delivered a standout performance and we returned to double-digit growth in the Emerging Markets.

“Our healthy balance sheet, good cash generation and increased dividend demonstrate the robust foundations underpinning our business.”

2018 set to be another year of “improved performance”

He added: “In 2018 I expect Smith & Nephew to build on 2017 by delivering another year of improved performance driven by our strong product portfolio and pipeline of innovative products.”

The company expects underlying revenues to increase by another 3-4% in 2018, while trading profit margins is forecasts to improve by a further 30-70 basis points.

Smith & Nephew is also implementing an efficiency programme – Accelerating Performance and Execution – this year which it hopes will deliver cost savings of US$160mln a year by 2022. 

View full SN. profile View Profile

Smith & Nephew PLC Timeline

Related Articles

1506367758_shutterstock_118491940.jpg
September 26 2017
The firm received an order for its clinical research use only (RUO) kits from a large, multinational pharma company
scientist looking through a microscope
October 31 2017
As of March, ReNeuron had £53mln in cash equivalents but its market value is not too much above that....
Summit
January 25 2018
Interim results for a study on ezutromid revealed a “statistically significant and meaningful” reduction in muscle damage, the company said

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use